CClinicalTrials.gg
Status unknownNCT00713024Updated Jun 29, 2010

Patterns of Cerebral Activation to Innocuous and Noxious Heat Stimulations in Neuropathic Pain

An observational study in Neuropathic Pain, sponsored by National Taiwan University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-29.

Sponsored by National Taiwan University Hospital · Observational

The sponsor has not verified this record recently (last verified Jun 2010), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Ages
20 Years to 70 Years
Sex
All
01

Study summary

Patients with neuropathic pain exhibit hyperalgesia and allodynia. Although both peripheral and central determinants are recognized for the pathophysiological basis of neuropathic pain following peripheral injury, the modulating effect on pain processing in brain by peripheral mechanisms remains elusive. Here, we will systematically compare the sensory symptoms and brain activation to innocuous and noxious thermal stimulation applied to the distal leg, foot dorsum or forearm between patients with peripheral neuropathy and healthy controls. Functional magnetic resonance imaging will be used to define brain activation to somatic stimulation with noxious and innocuous stimuli. The blood-oxygenation-level-dependent signals will be correlated with visual analogue scale scores and sensory and affective components obtained from the Short-Form McGill Pain Questionnaire. Brain activation during thermal stimulation in patients with neuropathic pain will be clarified, and we will also analyze the potential relationships between the topography, quality and intensity of the different painful symptoms (i.e. spontaneous ongoing pain, paroxysmal pain, allodynia, hyperalgesia) and the magnitude and pattern of brain activation during thermal stimulation. This will add in our understanding in the pathophysiology of brain modulation in pain and provide clinically useful message toward the potential therapeutics in the management of neuropathic pain.

Read the detailed description

Many patients with neuropathic pain exhibit hyperalgesia and allodynia. In various pain syndromes, neuropathic pain is among the most difficult to treat. Previous studies show that the development of secondary hyperalgesia results from abnormal processing of nociceptor input after injuries of the peripheral nervous system. However, the modulating effect on pain processing in brain by peripheral mechanisms remains elusive, and only few studies investigate the issue.

Evidences suggest that lesions of the spinothalamocortical pathway may be necessary for developing the central pain, indicating indirect changes in excitability due to alterations of pain modulatory systems. Previous anatomical, physiological, and lesion studies have revealed an extensive cortical network associated with sensory, cognitive, and affective aspects of pain, including primary somatosensory cortex, secondary somatosensory cortex, insular cortex, and anterior cingulate cortex. Moreover, a recent study reported that neuropathic pain might influence brain organization. Therefore, it would be intriguing to know whether and how the brain processes pain in patients with neuropathic pain.

We hypothesize that neuropathic pain elicited by the peripheral neuropathy results in hyperexcitability of the pain matrix (i.e. central sensitization) due to alterations of pain modulatory systems. Patients with peripheral neuropathy and healthy volunteers will be recruited in this study. Peripheral neuropathy is defined according to the neuropathic symptoms and signs. For healthy volunteers, clinical history will be evaluated by questionnaires and neurological examinations to exclude any neuropsychiatric disorder or pain condition.

To assess the severity of different neuropathic symptoms,patients with neuropathic pain will fill out the Neuropathic Pain Symptom Inventory (NPSI). Each subject will receive detailed sensory examination to evaluate the integrity of small-diameter and large-diameter sensory fibers. To measure thresholds of thermal and vibratory sensations, we will perform quantitative sensory testing (QST) by the method of level using a Thermal Sensory Analyser and Vibratory Sensory Analyser (Medoc Advanced Medical System, Minneapolis, MN, USA) following an established protocol. Thermal thresholds will be recorded on the toe, and vibratory thresholds recorded on the lateral malleolus. These values will be compared with normative values for the age, which had been documented previously.

Functional magnetic resonance imaging (fMRI) will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). A high resolution T1 weighted scan of the entire brain in trans-axial orientation will be obtained to provide anatomical information for the superimposed functional activation maps. Echo Planar Imaging will be used for the acquisition of the functional data.

We will use a CHEP stimulator (Medoc Ltd, Ramat Yishai, Israel) to deliver thermal stimulation. The 27 mm diameter thermode is comprised of a heating thermofoil (Minco Products, Inc., Minneapolis, MN) that is covered with a thermoconductive plastic. The stimulus temperatures given throughout this report will be referred to the temperature of the thermofoil. Cooling will begin immediately following attainment of the pre-fixed target temperature. Individual heat pain threshold (HPT) will be measured before fMRI scans. Noxious heat and innocuous heat will be applied within the distal leg, foot dorsum or forearm. The thermode will be remained at the same site during each block of functional MRI scans. Several pretests will be applied before CHEP recording to eliminate expectation effects. To avoid sensitization and desensitization, low intensity stimuli will precede high intensity stimuli at each block.

Each imaging session will be consisted of one high-resolution anatomical scan and three functional scanning runs, with 5-min intersession interval. During the scanning, five thermal stimuli will be applied by CHEP stimulator to the right dorsal foot. To avoid sensitization, habituation and tissue damage, the stimulation temperature will be applied in a random fashion, and the stimulation site will be changed slightly after each stimulus. After 12-s stimulation, the temperature will be cooling, with a subsequent 36-s interstimulus interval. After each fMRI session, subjects will be asked to rate the intensity and unpleasantness of received pain stimulus. The average rating values will be indicated after the scan on a computer driven visual analogue scale (VAS) ranging from 0 to 10 (0, no sensation; 1, slight intense; 2, innocuous warmth; 3, innocuous heat; 4, slight pain; 5, mild pain; 7, moderate-strong pain; 9, severe pain; 10, unbearable pain), and the intensity and unpleasantness of received pain will be assessed using the Short-Form McGill Pain Questionnaire (SFMPQ).

All data will be processed using the Statistical Parametric Mapping software (SPM2, Wellcome Department of Cognitive Neurology, London UK). fMRI data series will be realigned and resliced with sinc interpolation to correct for motion artifacts. Scans with sudden head movements of more than 2 mm will be omitted. To enable intersubject analysis, the functional data will be coregistered to the anatomical scan and transformed into a reference space according to the MNI template of SPM2 by normalization using sinc interpolation. This template has been determined from 305 MRI scans of healthy subjects at the Montreal Neurological Insitute. The resampled voxel volume of the normalized images is 2 x 2 x 2 mm. Subsequently, data will be smoothed with an isotropic Gaussian kernel of 8 mm full-width at half maximum to reduce high frequency noise and to account for anatomical variances. Condition-specific effects will be estimated with the general linear model using a boxcar approach convolved with the hemodynamic response function. High pass filtering will remove low frequency noise and low pass filtering will account for serial autocorrelations of the data.

We will analyze the data on an individual (subject per subject) basis and across subjects (group analysis) using a cross-subjects variance (random effect analysis). We will compute different contrasts between cerebral responses during innocuous and noxious heat stimulation. Data from each stimulation will be pooled for group statistical comparisons. A group activation map will be constructed by performing a conjunction analysis to measure the spatial overlap of activation across subjects. A single design matrix, including 3 sessions of all subjects, will be generated due to the limited number of experiments representing a fixed-effects model analysis. Statistical parametric maps will be generated as t-contrasts and corrected for multiple comparisons according to the random field theory with P \< 0.05. The threshold for the Z maps is 3.09 (P \< 0.001) for individual subject analysis. Significant clusters have to show a minimum extension volume of 10 voxels. For group analysis, parametric maps will be constructed using the same contrast and spatial extent but we will use a corrected threshold of P \< 0.05.

02

Conditions studied

  • Neuropathic Pain

Browse trials for

Keywords

  • Pain; Functional neuroimaging; Neuropathy; Thermal sensation
03

In context

Neuralgia

1,287 studies on the registry are indexed under Neuralgia; 256 are open to participants now.

This study's planned enrollment of 150 is above the median of 100 across 260 observational studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will recruit healthy control subjects and patients having neuropathic pain in the current study.

Inclusion criteria

  • patients having neuropathic pain
  • healthy control subjects

Exclusion criteria

Exclusion Criteria:

  • subjects with pacemaker implantation
  • patients with neuropsychiatric disorder except neuropathic pain
  • subjects with agoraphobia
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)

Groups and cohorts

  • 1

    Healthy control subjects

  • 2

    Patients having neuropathic pain

06

Study locations

1 of 1 sites recruiting
  • Department of Neurology, National Taiwan University Hospital
    Taipei, 100, Taiwan
    • Sung-Tsang Hsieh, MD, PhD · Contact · shsieh@ntu.edu.tw · 886-2-23123456
    • Ming-Tsung Tseng, M.D · Principal investigator
    Recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00713024
Lead sponsor
National Taiwan University Hospital
First posted
Jul 11, 2008
Start date
Jan 2008
Primary completion
Dec 2010 (estimated)
Completion
Dec 2010 (estimated)
Last update
Jun 29, 2010

Study contacts

Sung-Tsang Hsieh, M.D., PhD
Contact
shsieh@ntu.edu.tw
886-2-23123456 ext. 8182
Sung-Tsang Hsieh, MD, PhD
study director · Department of Neurology, National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion